IS5245A - Lyfjablanda úr ómeprasól - Google Patents

Lyfjablanda úr ómeprasól

Info

Publication number
IS5245A
IS5245A IS5245A IS5245A IS5245A IS 5245 A IS5245 A IS 5245A IS 5245 A IS5245 A IS 5245A IS 5245 A IS5245 A IS 5245A IS 5245 A IS5245 A IS 5245A
Authority
IS
Iceland
Prior art keywords
omeprazole
pharmaceutical preparation
pharmaceutical
preparation
Prior art date
Application number
IS5245A
Other languages
English (en)
Other versions
IS2856B (is
Inventor
Erickson Magnus
Josefsson Lars
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407122&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS5245(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of IS5245A publication Critical patent/IS5245A/is
Publication of IS2856B publication Critical patent/IS2856B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IS5245A 1997-05-28 1999-11-11 Lyfjablanda úr ómeprasól IS2856B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702000A SE9702000D0 (sv) 1997-05-28 1997-05-28 New pharmaceutical formulation
PCT/SE1998/000922 WO1998053803A1 (en) 1997-05-28 1998-05-18 Pharmaceutical formulation of omeprazole

Publications (2)

Publication Number Publication Date
IS5245A true IS5245A (is) 1999-11-11
IS2856B IS2856B (is) 2013-11-15

Family

ID=20407122

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5245A IS2856B (is) 1997-05-28 1999-11-11 Lyfjablanda úr ómeprasól

Country Status (40)

Country Link
US (1) US6090827A (is)
EP (1) EP0984773B1 (is)
JP (1) JP4649001B2 (is)
KR (1) KR100540721B1 (is)
CN (1) CN1123338C (is)
AR (1) AR012698A1 (is)
AT (1) ATE234078T1 (is)
AU (1) AU722879B2 (is)
BR (1) BR9809484A (is)
CA (1) CA2290531C (is)
CZ (1) CZ298972B6 (is)
DE (1) DE69812089T2 (is)
DK (1) DK0984773T3 (is)
DZ (1) DZ2494A1 (is)
EE (1) EE03903B1 (is)
EG (1) EG24044A (is)
ES (1) ES2195342T3 (is)
HR (1) HRP980260B1 (is)
HU (1) HU229154B1 (is)
ID (1) ID24654A (is)
IL (1) IL132895A0 (is)
IS (1) IS2856B (is)
MA (1) MA26497A1 (is)
MY (1) MY122298A (is)
NO (1) NO328100B1 (is)
NZ (1) NZ500886A (is)
PL (1) PL194634B1 (is)
PT (1) PT984773E (is)
RS (1) RS49629B (is)
RU (1) RU2207121C2 (is)
SA (1) SA98190304B1 (is)
SE (1) SE9702000D0 (is)
SI (1) SI0984773T1 (is)
SK (1) SK286625B6 (is)
TN (1) TNSN98068A1 (is)
TR (1) TR199902890T2 (is)
TW (1) TW575435B (is)
UA (1) UA71541C2 (is)
WO (1) WO1998053803A1 (is)
ZA (1) ZA984178B (is)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
ATE526022T1 (de) * 1998-04-20 2011-10-15 Eisai R&D Man Co Ltd Stabilisierte zusammenstellungen die benzimidazole enthalten
SE9803772D0 (sv) * 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
SE9902386D0 (sv) * 1999-06-22 1999-06-22 Astra Ab New formulation
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
TWI268779B (en) 1999-10-20 2006-12-21 Eisai Co Ltd Method for stabilizing benzimidazole-based compounds
US20040092511A1 (en) * 1999-12-10 2004-05-13 Billstein Stephan Anthony Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
JP2002234842A (ja) * 2001-02-09 2002-08-23 Kyowa Yakuhin Kogyo Kk 内服腸溶性製剤
MXPA04007169A (es) * 2002-01-25 2004-10-29 Santarus Inc Suministro transmucosal de inhibidores de bomba de protones.
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
FR2843121B3 (fr) 2002-08-02 2004-09-10 Rhodia Chimie Sa Agent ignifugeant, procede de preparation et l'utilisation de cet agent
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20040146558A1 (en) * 2003-01-28 2004-07-29 Kyowa Pharmaceutical Co., Ltd. Oral enteric-coated preparation
CN1761465B (zh) * 2003-01-29 2010-10-13 武田药品工业株式会社 制备被覆制剂的方法
JP4567340B2 (ja) * 2003-01-29 2010-10-20 武田薬品工業株式会社 被覆製剤の製造方法
RU2359671C2 (ru) * 2003-01-29 2009-06-27 Такеда Фармасьютикал Компани Лимитед Способ получения препарата с покрытием
PL377403A1 (pl) * 2003-01-29 2006-02-06 Takeda Pharmaceutical Company Limited Sposób wytwarzania preparatu powlekanego
WO2004073654A2 (en) * 2003-02-20 2004-09-02 Santarus, Inc. A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained supression of gastric acid
RU2375048C2 (ru) * 2003-07-17 2009-12-10 Д-Р Редди'С Лабораторис Инк. Фармацевтическая композиция с набухающим покрытием
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
CN1311824C (zh) * 2004-04-21 2007-04-25 常州市第四制药厂有限公司 奥美拉唑肠溶微粒制剂及制备方法
US8815916B2 (en) * 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
DE602005013372D1 (de) * 2005-07-29 2009-04-30 Rottapharm Spa Kombination aus Itriglumid und PPI zur Behandlung von gastrointestinalen- und assozierten Krankheiten
AU2007266574A1 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
KR101436516B1 (ko) * 2007-07-23 2014-09-02 주식회사태평양제약 코팅된 펠렛을 함유하는 현탁정 및 이의 제조방법
AU2008304033B2 (en) * 2007-09-28 2014-05-01 Ctc Bio, Inc. Pharmaceutical composition containing esomeprazole
CA2720800C (en) * 2008-03-28 2013-07-30 Ferrer Internacional S.A. Capsule for the prevention of cardiovascular diseases
AU2009282888C1 (en) 2008-08-19 2014-01-23 Xenoport, Inc. Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
US20140348915A9 (en) 2012-08-22 2014-11-27 Xenoport, Inc. Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
US10945984B2 (en) 2012-08-22 2021-03-16 Arbor Pharmaceuticals, Llc Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
CN102961356A (zh) * 2012-12-11 2013-03-13 山西云鹏制药有限公司 一种含奥美拉唑的蓝色肠溶片剂的制备方法
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
TW201516020A (zh) 2013-09-06 2015-05-01 Xenoport Inc （ｎ，ｎ－二乙基胺甲醯基）甲基（２ｅ）丁－２－烯－１，４－二酸甲酯之晶形、合成方法及用途
US20150079180A1 (en) * 2013-09-18 2015-03-19 Xenoport, Inc. Nanoparticle compositions of dimethyl fumarate
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2021153525A1 (ja) 2020-01-27 2021-08-05 東和薬品株式会社 エソメプラゾール経口製剤およびその製造方法
KR102432084B1 (ko) 2021-11-16 2022-08-12 알리코제약(주) S-오메프라졸을 함유하는 안정성이 개선되고 소형화된 정제
EP4598528A1 (en) 2022-10-04 2025-08-13 Arsenil Zabirnyk Inhibition of aortic valve calcification

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
JPH05255088A (ja) * 1991-11-05 1993-10-05 Yoshitomi Pharmaceut Ind Ltd 抗潰瘍剤含有製剤
JP2669446B2 (ja) * 1992-03-23 1997-10-27 信越化学工業株式会社 医薬品コーティング液用原料粉粒体
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
JPH0733659A (ja) * 1992-07-17 1995-02-03 Yoshitomi Pharmaceut Ind Ltd 抗潰瘍剤含有製剤
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
JP3350054B2 (ja) * 1994-07-08 2002-11-25 アストラゼネカ・アクチエボラーグ 複数単位の錠剤化された剤形▲ｉ▼
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms

Also Published As

Publication number Publication date
KR100540721B1 (ko) 2006-01-10
JP2002500665A (ja) 2002-01-08
HU229154B1 (en) 2013-09-30
PT984773E (pt) 2003-07-31
EE9900540A (et) 2000-06-15
DE69812089T2 (de) 2004-03-04
BR9809484A (pt) 2000-06-20
ES2195342T3 (es) 2003-12-01
IS2856B (is) 2013-11-15
NZ500886A (en) 2001-11-30
AU7680398A (en) 1998-12-30
HK1025744A1 (en) 2000-11-24
EP0984773B1 (en) 2003-03-12
TW575435B (en) 2004-02-11
NO328100B1 (no) 2009-12-07
IL132895A0 (en) 2001-03-19
EP0984773A1 (en) 2000-03-15
HRP980260B1 (en) 2003-10-31
US6090827A (en) 2000-07-18
JP4649001B2 (ja) 2011-03-09
MA26497A1 (fr) 2004-12-20
DZ2494A1 (fr) 2003-01-25
CA2290531C (en) 2006-12-12
NO995809D0 (no) 1999-11-26
CZ298972B6 (cs) 2008-03-26
PL337237A1 (en) 2000-08-14
DE69812089D1 (de) 2003-04-17
SI0984773T1 (en) 2003-10-31
PL194634B1 (pl) 2007-06-29
SA98190304B1 (ar) 2006-10-11
CZ420299A3 (cs) 2000-05-17
DK0984773T3 (da) 2003-07-07
KR20010013104A (ko) 2001-02-26
SE9702000D0 (sv) 1997-05-28
SK159099A3 (en) 2000-06-12
TNSN98068A1 (fr) 2005-03-15
AU722879B2 (en) 2000-08-10
ID24654A (id) 2000-07-27
RU2207121C2 (ru) 2003-06-27
CN1123338C (zh) 2003-10-08
MY122298A (en) 2006-04-29
UA71541C2 (uk) 2004-12-15
WO1998053803A1 (en) 1998-12-03
CA2290531A1 (en) 1998-12-03
SK286625B6 (sk) 2009-02-05
AR012698A1 (es) 2000-11-08
NO995809L (no) 2000-01-28
HUP0002182A2 (hu) 2002-05-29
YU60899A (sh) 2002-06-19
EE03903B1 (et) 2002-12-16
ATE234078T1 (de) 2003-03-15
EG24044A (en) 2008-04-13
HRP980260A2 (en) 1999-02-28
HUP0002182A3 (en) 2003-02-28
RS49629B (sr) 2007-08-03
TR199902890T2 (xx) 2000-02-21
ZA984178B (en) 1998-11-30
CN1258217A (zh) 2000-06-28

Similar Documents

Publication Publication Date Title
IS5245A (is) Lyfjablanda úr ómeprasól
NO994757D0 (no) FramgangsmÕte for oral administrasjon av proteiner
EE04418B1 (et) Moksifloksatsiini farmatseutiline preparaat
CY2012029I1 (el) Νεα μορφη της s-ομεπραζολης
IS5953A (is) Lyfjablöndur úr örgerðum eplerenonum
ID23874A (id) Obat
NO980546D0 (no) Farmasöytiske midler
DK1466615T3 (da) Farmaceutisk præparat
NO995251D0 (no) FremgangsmÕte for administrering av haloterapi
EE04154B1 (et) Omeprasooli valmistamise meetod
FI953887L (fi) Kefaklorin farmaseuttisia formulaatioita
ID16781A (id) Formulasi-formulasi farmasi
ID29294A (id) Komposisi farmasi
DE69926012D1 (de) Arzneizubereitungen
DK1041966T3 (da) Farmaceutiske præparater omfattende zafirlukast
DE69906934D1 (de) Arzneizubereitungen
EP1142589A4 (en) Medicinal preparations
FI951155L (fi) Farmaseuttinen valmiste
ID23531A (id) Komposisi farmasi
FI974235A0 (fi) Ny bestaemningsmetod
FI3862U1 (fi) Geelimuotoinen farmaseuttinen valmiste
SK1380U (sk) Farmaceutický preparát
BR9612652A (pt) Forma de administração farmacêutica
BR1100755A (pt) composição farmacêutica
ID21180A (id) Senyawa-senyawa farmasi